By Professor Jason Grebely

Conference Abstracts

Alavi M; Valerio H; Law M; Lockart I; Danta M; Grebely J; Amin J; Hajarizadeh B; George J; Dore G, 2022, 'Incidence and risk factors of hepatitis C liver morbidity and mortality in the era of direct-acting antiviral therapies: a population-based linkage study', in JOURNAL OF HEPATOLOGY, ELSEVIER, ENGLAND, London, Vol. 77, pp. S568 - S569, presented at International Liver Congress, ENGLAND, London, 22 June 2022 - 26 June 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000826275103096&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Farrell M; Shahbazi J; Byrne M; Larance B; Lintzeris N; Nielsen S; Grebely J; Shanahan M; Lancaster K; Dore GJ; Ali R; Dunlop AJ; Rodgers C; Degenhardt L, 2021, 'AN OPEN-LABEL, MULTICENTRE, SINGLE-ARM TRIAL OF MONTHLY INJECTIONS OF EXTENDED RELEASE BUPRENORPHINE IN PEOPLE WITH OPIOID USE DISORDER: THE COLAB STUDY', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 40, pp. S71 - S72, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000715073200178&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Santo T; Clark B; Hickman M; Grebely J; Campbell G; Sordo L; Chen A; Tran LT; Bharat C; Padmanathan P; Cousins G; Dupouy J; Kelty E; Muga R; Nosyk B; Jeongmin ; Pavarin R; Farrell M; Degenhardt L, 2021, 'ASSOCIATION OF OPIOID AGONIST TREATMENT WITH ALL-CAUSE MORTALITY AND SPECIFIC CAUSES OF DEATH AMONG PEOPLE WITH OPIOID DEPENDENCE: A SYSTEMATIC REVIEW AND META-ANALYSIS', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 40, pp. S131 - S131, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000715073200320&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Dawson O; Jaworski A; Kerr S; Grebely J, 2021, 'HEPATITIS C EDUCATION IN DRUG AND ALCOHOL SETTINGS: PRELIMINARY EVALUATION FINDINGS FROM A NATIONAL ONLINE TRAINING PROGRAM', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 40, pp. S63 - S63, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000715073200158&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Farrell M; Shahbazi J; Byrne M; Larance B; Lintzeris N; Nielsen S; Grebely J; Shanahan M; Lancaster K; Dore GJ; Ali R; Dunlop AJ; Rodgers C; Degenhardt L, 2021, 'OVERVIEW AND FINDINGS OF THE COLAB STUDY: AN OPEN-LABEL IMPLEMENTATION STUDY OF SUBLOCADE TREATMENT IN SPECIALIST AND PRIMARY CARE SETTINGS IN AUSTRALIA', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 40, pp. S25 - S25, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000715073200062&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lazarus J; Picchio C; Byrne C; Crespo J; Colombo M; Cooke G; Dore G; Grebely J; Ward J; White T; Dillon J, 2021, 'A global systematic review of efforts to accelerate the elimination of hepatitis C virus (HCV) through micro-elimination', in JOURNAL OF HEPATOLOGY, ELSEVIER, Vol. 75, pp. S661 - S662, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000667753801295&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

He S; Alavi M; Hajarizadeh B; Grebely J; Law M; Amin J; George J; Danta M; Dore G, 2021, 'comparison of hbv-related hcc incidence between entecavir and tenofovir treated cohorts: a population-based study', in JOURNAL OF HEPATOLOGY, ELSEVIER, Vol. 75, pp. S515 - S516, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000667753801051&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Grebely J; Conway B; Litwin AH; Dalgard O; Shibolet O; Nahass RG; Altice F; Gane EJ; Luetkemeyer A; Peng C-Y; Iser D; Gendrano IN; Kelly M; Hwang P; Asante-Appiah E; Barr E; Robertson MN; Platt H; Dore G, 2019, 'DRUG USE AND REINFECTION DURING AND FOLLOWING HCV TREATMENT WITH ELBASVIR/GRAZOPREVIR AMONG PATIENTS RECEIVING OPIOID AGONIST THERAPY: FINAL RESULTS FROM THE CO-STAR STUDY', in HEPATOLOGY, WILEY, MA, Boston, Vol. 70, pp. 955A - 956A, presented at Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, MA, Boston, 08 November 2019 - 12 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000488653503272&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Aghemo A; Negro F; Gschwantler M; Asselah T; Bondin MI; Crown ED; Mancine M; Zhang Z; Flisiak R; Grebely J; Brau N; Sterling RK, 2019, 'FROM CLINICAL TRIALS TO REAL-WORLD EVIDENCE: SIMILAR VIROLOGIC CURE RATES AND SAFETY OUTCOMES FOLLOWING TREATMENT WITH GLECAPREVIR/PIBRENTASVIR AMONG PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION AND RECENT DRUG USE', in HEPATOLOGY, WILEY, MA, Boston, Vol. 70, pp. 932A - 933A, presented at Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, MA, Boston, 08 November 2019 - 12 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000488653503237&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Howe A; De Salazar A; Aragri M; Popping S; Fourati S; Tay E; Rodrigo C; Cunningham E; Kjellin M; Fernando Fay F; Newton E; Sfalcin J; Gomes P; Boucher CA; De Knegt R; Poljak M; Lunar M; Salmon D; Usubillaga R; Sayan M; Mor O; Seguin-Devaux C; Lloyd A; Pawlotsky J-M; Grebely J; Lennerstrand J; Knops E; Kaiser R; Chulanov V; Rincon P; Martinez-Sapina A; Galera C; Douglas M; Silberstein FC; Harrigan R; Garcia Garcia F, 2019, 'GENOTYPE MISCLASSIFICATION NEGATIVELY IMPACT THE CHOICE OF REGIMENS AND TREATMENT OUTCOMES IN THE MANAGEMENT OF HEPATITIS C', in HEPATOLOGY, WILEY, MA, Boston, Vol. 70, pp. 318A - 319A, presented at Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, MA, Boston, 08 November 2019 - 12 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000488653501070&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Fourati S; Silberstein FC; Howe A; De Salazar A; Popping S; Di Maio VC; Tay E; Rodrigo C; Cunningham E; Kjellin M; Sfalcin J; Gomes P; Poljak M; Lunar M; Sayan M; Mor O; Salmon D; Usubillaga R; Seguin-Devaux C; Boucher CA; Poiteau L; Lloyd A; Grebely J; Lennerstrand J; Kaiser R; Zhigalkina P; Fernando Fay F; Aragri M; Chulanov V; Garcia-Deltoro M; Cabezas J; Carlos Alados J; De Knegt RJ; Douglas M; Garcia FG; Harrigan R; Pawlotsky J-M, 2019, 'HCV RESISTANCE PATTERNS IN A WORLDWIDE NETWORK OF COHORTS OF GT-3a INFECTED PATIENTS', in HEPATOLOGY, WILEY, MA, Boston, Vol. 70, pp. 180A - 181A, presented at Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, MA, Boston, 08 November 2019 - 12 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000488653500277&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

He S; Dore G; Law M; Heahter V; Grebely J; Amin J; Hajarizadeh B; George J; Danta M; Alavi M, 2019, 'IMPROVED SURVIVAL FOLLOWING HEPATITIS C-RELATED HEPATOCELLULAR CARCINOMA DIAGNOSIS IN THE DIRECT-ACTING ANTIVIRAL THERAPY ERA IN NEW SOUTH WALES, AUSTRALIA', in HEPATOLOGY, WILEY, MA, Boston, Vol. 70, pp. 906A - 906A, presented at Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, MA, Boston, 08 November 2019 - 12 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000488653503195&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Popping S; Fourati S; Howe A; Di Maio VC; Tay E; Rodrigo C; Cunningham E; Kjellin M; Sfalcin J; Gomes P; Poljak M; Lunar M; Sayan M; Mor O; Salmon D; Usubillaga R; Omar M; Garcia-Bujalance S; Tellez F; Fuentes A; Seguin-Devaux C; Soulier A; Lloyd A; Grebely J; Aragri M; Lennerstrand J; Kaiser R; Zhigalkina P; Chulanov V; De Knegt RJ; Douglas M; Silberstein FC; Harrigan R; Garcia FG; Boucher CA; Pawlotsky J-M, 2019, 'THE GLOBAL PREVALENCE OF RESISTANCE ASSOCIATED SUBSTITUTIONS (RASS) IN "UNUSUAL" HCV SUBTYPES', in HEPATOLOGY, WILEY, MA, Boston, Vol. 70, pp. 77A - 78A, presented at Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, MA, Boston, 08 November 2019 - 12 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000488653500117&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Matthews G; Bhagani S; Van der Valk M; Rockstroh JK; Kim AY; Thurnheer C; Feld JJ; Bruneau J; Gane EJ; Hellard M; Grebely J; Applegate T; Marks P; Martinello M; Petoumenos K; Dore G, 2019, 'SHORT COURSE DURATION SOFOSBUVIR/VELPATASVIR IS INFERIOR TO STANDARD DURATION THERAPY IN THE TREATMENT OF RECENTLY ACQUIRED HCV INFECTION: RESULTS FROM REACT STUDY', in HEPATOLOGY, WILEY, MA, Boston, Vol. 70, pp. 1487A - 1488A, presented at 70th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, MA, Boston, 08 November 2019 - 12 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000500824000056&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Gibbs D; Larney S; Grebely J; Butler K; Sutherland R; Degenhardt L; Kelly G; Karlsson A; Uporova J; Bruno R; Salom C; Dietze PM; Lenton S; Farrell M; Peacock A, 2019, 'HEPATITIS C VIRUS CASCADE OF CARE AMONG PEOPLE WHO INJECT DRUGS: A CROSS-SECTIONAL STUDY OF CHARACTERISTICS ASSOCIATED WITH HCV TESTING AND TREATMENT IN AUSTRALIA', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 38, pp. S48 - S48, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000494890100120&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Law M; Reid H; Janjua N; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore GJ; Grebely J, 2019, 'HEPATITIS C VIRUS REINFECTION FOLLOWING ANTIVIRAL TREATMENT AMONG PEOPLE WHO USE OR INJECT DRUGS: A SYSTEMATIC REVIEW AND META-ANALYSIS', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 38, pp. S50 - S51, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000494890100127&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Larance B; Degenhardt L; Grebely J; Nielsen S; Bruno R; Dietze PM; Lancaster K; Larney S; Santo T; Shanahan M; Memedovic S; Ali R; Farrell M, 2019, 'PERCEPTIONS OF EXTENDED-RELEASE BUPRENORPHINE INJECTIONS FOR OPIOID DEPENDENCE PRIOR TO AVAILABILITY IN AUSTRALIA: A CROSS-SECTIONAL SURVEY OF PEOPLE WHO USE OPIOIDS REGULARLY', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 38, pp. S63 - S64, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000494890100159&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hajarizadeh B; Marshall AD; Grebely J; Dore GJ; Treloar C; Corry A; Hayllar J; Byrne J, 2019, 'SYMPOSIUM: ENHANCING HEPATITIS C CARE AMONG PEOPLE WHO INJECT DRUGS', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 38, pp. S8 - S9, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000494890100017&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

He S; Dore G; Law M; Valerio H; Grebely J; Amin J; Hajarizadeh B; George J; Danta M; Alavi M, 2019, 'Improved survival after hepatitis C-related hepatocellular carcinoma diagnosis in the direct-acting antiviral therapy era in New South Wales, Australia', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, Vol. 34, pp. 82 - 82, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000483843100132&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Reid H; Law M; Janjua N; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore G; Grebely J, 2019, 'Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: A systematic review, meta-analysis, and meta-regression', in JOURNAL OF HEPATOLOGY, ELSEVIER, AUSTRIA, Vienna, Vol. 70, pp. E733 - E733, presented at International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), AUSTRIA, Vienna, 10 April 2019 - 14 April 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000463481703223&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Grebely J; Cunningham EB; Dalgard O; Hajarizadeh B; Conway B; Powis J; Bruneau J; Feld J; Read P; Cooper C; Amin J; Bruggmann P; Lacombe K; Stedman C; Hellard M; Marks P; Dunlop A; Moriggia A; Applegate T; Litwin A; Matthews G; Dore G, 2019, 'Reinfection following successful HCV DAA therapy among people with recent injecting drug use', in JOURNAL OF HEPATOLOGY, ELSEVIER, AUSTRIA, Vienna, Vol. 70, pp. E732 - E733, presented at International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), AUSTRIA, Vienna, 10 April 2019 - 14 April 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000463481703222&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Valerio H; Alavi M; Silk D; Treloar C; Milat A; Dunlop A; Holden J; Henderson C; Amin J; Read P; Degenhardt L; Dore G; Grebely J, 2019, 'Uptake of testing, linkage to care, and treatment for hepatitis C infection among people who inject drugs in Australia: The ETHOS Engage study', in JOURNAL OF HEPATOLOGY, ELSEVIER, AUSTRIA, Vienna, Vol. 70, pp. E42 - E42, presented at International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), AUSTRIA, Vienna, 10 April 2019 - 14 April 2019, http://dx.doi.org/10.1016/S0618-8278(19)30076-3

Grebely J; Litwin AH; Dalgard O; Gane EJ; Shibolet O; Conway B; Nahass R; Altice F; Luetkemeyer A; Peng C-Y; Iser D; Gendrano IN; Huang H-C; Kelly MM; Hwang P; Barr E; Robertson MN; Platt H; Dore G, 2018, 'HCV Reinfection and Injecting Risk Behavior Following Elbasvir/Grazoprevir Treatment in Patients on Opioid Agonist Therapy: Co-STAR Part B', in HEPATOLOGY, WILEY, CA, San Francisco, Vol. 68, pp. 35A - 35A, presented at Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, CA, San Francisco, 09 November 2018 - 13 November 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000446020500053&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Colledge S; Peacock A; Leung J; Grebely J; Hickman M; Farrell M; Larney S; Degenhardt L, 2018, 'NON-FATAL OVERDOSE PREVALENCE AMONG PEOPLE WHO INJECT DRUGS - A MULTI-STAGE SYSTEMATIC REVIEW AND META-ANALYSIS OF RECENT EVIDENCE', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 37, pp. S23 - S23, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000449495000060&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Jacka B; Larney S; Hoj S; Degenhardt L; Krajden M; Janjua N; Grebely J; Bruneau J, 2018, 'Estimating the number of people who inject drugs and the coverage of harm reduction services in Canada', in JOURNAL OF VIRAL HEPATITIS, WILEY, CANADA, Toronto, Vol. 25, pp. 131 - 131, presented at 16th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD), CANADA, Toronto, 14 June 2018 - 17 June 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000435101000220&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Dalgard O; Grebely J; Conway B; Cunningham E; Bruggmann P; Hajarizadeh B; Amin J; Marks P; Quiene S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop A; Bruneau J; Hellard ME; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Litwin A; Dillon J; Read P; Gane E; Dore GJ, 2018, 'Sofosbuvir and Velpatasvir for Hepatitis C Virus Infection in People with Recent Injecting Drug Use (Simplify): An Open-Label, Single-Arm, Phase 4, Multicentre Trial', in HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS, PACINI EDITORE, Vol. 20, pp. 14 - 14, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000440974900004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Dalgard O; Grebely J; Feld JJ; Wyles D; Sulkowski M; Ni L; Llewellyn J; Soyemi T; Sajed N; Stamm LM; Hyland RH; McNally J; Brainard DM; Jacobson I; Zeuzem S; Bourliere M; Foster G; Afdhal N; Dore GJ, 2018, 'Sofosbuvir-Based Direct-Acting Antiviral Therapies for Hcv in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies', in HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS, PACINI EDITORE, Vol. 20, pp. 13 - 14, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000440974900003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Trickey A; Fraser H; Lim AG; Walker J; Peacock A; Colledge S; Leung J; Grebely J; Larney S; Degenhardt L; Hickman M; May M; Vickerman P, 2018, 'Comparing the prevention gains of different treatment strategies at the global, regional, and country level: a modelling study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, FRANCE, Paris, Vol. 68, pp. S179 - S180, presented at International Liver Congress (ILC), FRANCE, Paris, 11 April 2018 - 15 April 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000461068600354&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Trickey A; Fraser H; Lim AG; Walker J; Peacock A; Colledge S; Leung J; Grebely J; Larney S; Degenhardt L; Hickman M; Vickerman P, 2018, 'The contribution of injecting drug use to Hepatitis C virus transmission globally, regionally, and at country level: a modelling study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, FRANCE, Paris, Vol. 68, pp. S179 - S179, presented at International Liver Congress (ILC), FRANCE, Paris, 11 April 2018 - 15 April 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000461068600353&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Martinello M; Cerrone M; Bhagani S; Gane E; Orkin C; Cooke G; Dore GJ; Petoumenos K; Applegate TL; Tu E; Marks P; Pagani N; Schoolmeesters A; Grebely J; Nelson M; Matthews GV, 2018, 'TARGET3D: high efficacy of 8 weeks paritaprevir/ritonavir/ombitasvir and dasabuvir among people with recent genotype 1 HCV infection', in HIV MEDICINE, WILEY, Vol. 19, pp. S151 - S152, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000430174700440&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Grebely J; Dalgard O; Conway B; Cunningham E; Bruggmann P; Hajarizadeh B; Amin J; Marks P; Quiene S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop AJ; Bruneau J; Hellard ME; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Litwin AH; Dillon JF; Read P; Gane ED; Dore GJ, 2017, 'EFFICACY AND SAFETY OF SOFOSBUVIR/VELPATASVIR IN PEOPLE WITH CHRONIC HEPATITIS C VIRUS INFECTION AND RECENT INJECTING DRUG USE: THE SIMPLIFY STUDY', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 36, pp. 34 - 34, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000424000500085&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Pedrana A; Doyle J; Thompson A; Hellard ME; Grebely J; Bramwell F; Layton C; Livingston C; Jones S, 2017, 'SYMPOSIUM: IMPLEMENTING ELIMINATION STRATEGIES - INCREASE UPTAKE OF HEPATITIS C TESTING AND TREATMENT FOR PEOPLE WHO USE DRUGS', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 36, pp. 16 - 16, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000424000500035&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Brown AS; Welzel TM; Conway B; Negro F; Brau N; Grebely J; Puoti M; Kleine H; Pugatch D; Mensa FJ; Chen YJ; Lei Y; Lawitz E, 2017, 'Adherence to Pangenotypic Glecaprevir/Pibrentasvir Treatment and SVR12 in HCV-infected Patients: An Integrated Analysis of the Phase 2/3 Clinical Trial Program', in HEPATOLOGY, WILEY, DC, Washington, Vol. 66, pp. 114A - 115A, presented at 68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, DC, Washington, 20 October 2017 - 24 October 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000412089800199&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Foster GR; Grebely J; Sherman KE; Wang S; Dore GJ; Baumgarten A; Conway B; Jackson DF; Asselah T; Gschwantler M; Tomasiewicz K; Aguilar HI; Alami NN; Dumas EO; Hu Y; Mensa FJ, 2017, 'Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1-6 and Recent Drug Use', in HEPATOLOGY, WILEY, DC, Washington, Vol. 66, pp. 636A - 637A, presented at 68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, DC, Washington, 20 October 2017 - 24 October 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000412089801323&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Martinello M; Bhagani S; Gane EJ; Orkin C; Cooke G; Kulasegaram R; Shaw D; Hellard M; Tu E; Filep E; Petoumenos K; Marks P; Grebely J; Dore GJ; Nelson M; Matthews G, 2017, 'Shortened therapy of 8 weeks duration with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with acute and recent genotype 1 HCV infection: The TARGET3D Study', in HEPATOLOGY, WILEY, DC, Washington, Vol. 66, pp. 574A - 575A, presented at 68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, DC, Washington, 20 October 2017 - 24 October 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000412089801215&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Grebely J; Dalgard O; Conway B; Cunningham E; Bruggmann P; Hajarizadeh B; Amin J; Marks P; Quiene S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop AJ; Bruneau J; Hellard ME; Matthews GV; Powis J; Shaw D; Thurnheer CM; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Litwin A; Dillon J; Read P; Gane E; Dore GJ, 2017, 'Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S513 - S513, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000401056601271&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lamoury FM; Hajarizadeh B; Soker A; Martinez D; Quek C; Cunningham P; Catlett B; Cloherty GA; Marks P; Amin J; Grebely J; Dore GJ; Applegate TL, 2017, 'Hepatitis C virus core antigen and dried blood spots as simplified hepatitis C virus diagnostic tools', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S710 - S710, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)31901-3

Marshall AD; Nielsen S; Cunningham EB; Aghemo A; Alho H; Backmund M; Bruggmann P; Dalgard O; Flisiak R; Foster G; Gheorghe L; Goldberg D; Goulis I; Hickman M; Hoffmann P; Jancoriene L; Jarcuska P; Kaberg M; Makara M; Maimets M; Marinho R; Maticic M; Norris S; Olafsson S; Ovrehus A; Pawlotsky J-M; Pocock J; Robaeys G; Roncero C; Simonova M; Sperl J; Tait M; Tolmane I; Tomaselli S; van der Valk M; Vince A; Dore GJ; Lazarus JV; Grebely J, 2017, 'Restrictions for reimbursement of interferon-free direct-acting antiviral therapies for HCV infection in Europe', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S95 - S96, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)30450-6

Grebely J; Jacobson IM; Kayali Z; Verna EC; Shiffman ML; Hyland RH; Stamm LM; Huang KC; Brainard DM; McHutchison JG; Pol S; Chung RT; Bernstein DE; Dore G, 2017, 'SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S513 - S514, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000401056601272&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Bartlett SR; Grebely J; Eltahla AA; Reeves JD; Howe A; Miller V; Bull RA; Ceccherini-Silberstein F; Douglas MW; Dore GJ; Harrington P; Lloyd AR; Jacka B; Matthews GV; Wang GP; Pawlotsky J-M; Feld JJ; Schinkel J; Garcia F; Lennerstrand J; Applegate TL, 2017, 'Systematic review & expert guidance on methods for sequencing of hepatitis C virus for detection of direct-acting antiviral resistance', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S323 - S323, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)30970-4

Kwon AJ; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Estes C; Razavi H; Gray RT, 2017, 'O12 Australia could meet the WHO HCV elimination targets if the current rollout of DAA treatment is continued', in Journal of Virus Eradication, Elsevier BV, Vol. 3, pp. 5 - 5, http://dx.doi.org/10.1016/s2055-6640(20)30895-5

Dore G; Grebely J; Altice F; Litwin AH; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng C-Y; Conway B; Iser DM; Huang H-C; Gendrano IN; Kelly MM; Hwang P; Robertson M; Wahl J; Barr E; Platt HL, 2016, 'HCV reinfection and injecting risk behavior following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR Three Year Follow-up Study', in HEPATOLOGY, WILEY, MA, Boston, Vol. 64, pp. 431A - 431A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016

Grebely J; Marshall AD; Krahe M; Erratt A; Telenta J; Treloar C; Jones SC; Adey S; Bath N; How-Chow D; Byrne J; Harvey P; Dunlop AJ; Applegate TL; Lamoury F; Mowat Y; Jauncey M; Read P; Gilliver R; Smith J; Collie T; Dore GJ, 2016, 'A LIVER HEALTH PROMOTION INTERVENTION INTEGRATING NON-INVASIVE LIVER DISEASE SCREENING IN DRUG AND ALCOHOL SETTINGS: THE LIVERLIFE STUDY', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 35, pp. 40 - 40

Larney S; Grebely J; Degenhardt L; Amin J; Law M; Alavi M; Dore GJ; Law M, 2016, 'EXPOSURE TO OPIOID SUBSTITUTION THERAPY FOLLOWING HEPATITIS C NOTIFICATION: IMPLICATIONS FOR PROVISION OF ANTIVIRAL THERAPIES IN DRUG TREATMENT SETTINGS', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 35, pp. 48 - 48

Grebely J; Mauss S; Brown A; Bronowicki J-P; Puoti M; Wyles D; Natha M; Zhu Y; Yang J; Kreter B; Brainard DM; Yun C; Carr V; Dore GJ, 2016, 'SOFOSBUVIR/LEDIPASVIR WITH AND WITHOUT RIBAVIRIN IN PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION RECEIVING OPIOID SUBSTITUTION THERAPY: PHASE 3 ION TRAILS', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 35, pp. 40 - 41

Alavi M; Janjua N; Yu A; Grebely J; Aspinall E; Innes H; Valerio H; Hayes P; Krajden M; Amin J; Law M; George J; Goldberg D; Hutchinson S; Dore G, 2016, 'DOES ALCOHOL DEPENDENCY EXPLAIN DIFFERENCES IN RATES OF DECOMPENSATED CIRRHOSIS AMONG PEOPLE WITH A HEPATITIS C NOTIFICATION? AN INTERNATIONAL COMPARISON', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, Vol. 64, pp. S462 - S463, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)00776-5

Martinello M; Petoumenos K; Grebely J; Gane E; Hellard M; Shaw D; Sasdeusz J; Applegate T; Lamoury F; Yeung B; Maire L; Dore G; Matthews G, 2016, 'INCIDENCE OF HCV REINFECTION AMONG TREATED INDIVIDUALS WITH RECENTLY ACQUIRED INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, Vol. 64, pp. S620 - S621, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)01152-1

Alavi M; Grebely J; Micallef M; Dunlop A; Balcomb A; Day C; Treloar C; Bath N; Haber P; Dore G, 2015, 'P0883 : Treatment for hepatitis C virus infection among people who inject drugs in the opioid substitution setting: The ethos study', in Journal of Hepatology, Elsevier, AUSTRIA, Vienna, Vol. 62, pp. s673, presented at 50th International Liver Congress of the European-Association-for-the-Study-of-the-Liver, AUSTRIA, Vienna, 22 April 2015 - 26 April 2015, http://dx.doi.org/10.1016/s0168-8278(15)31085-0

Back to profile page